What is the clinical evidence from this study?

Study design: Cohort. Population: Type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease (n=2364). Intervention: Elevated Triglyceride-glucose (TyG) index vs. Lower TyG index. Primary outcome: Major adverse cardiovascular events (MACEs) (HR 1.71, 95% CI 1.26-2.33).

What question did this study set out to answer?

This study aims to evaluate the prognostic significance of the triglyceride-glucose index in forecasting major cardiovascular events among patients with Type 2 diabetes mellitus and MASLD.

June 21, 2026Cardiovascular DiabetologyOpen Access

Predictive significance of triglyceride-glucose index in forecasting adverse cardiovascular events among Type 2 diabetes mellitus patients with co-existing metabolic dysfunction-associated steatotic liver disease (MASLD): evidence from two cohort studies

View Full Paper

Ask AI

Bookmark

Key result

Elevated TyG index is linked to ~71% higher MACE risk in T2DM and MASLD.

HR 1.71
95% CI 1.26-2.33
n=2,364

Why the study?

Does an elevated triglyceride-glucose (TyG) index predict all-cause mortality and major adverse cardiovascular events in patients with concurrent T2DM and MASLD?

Population

2,364 patients with concurrent Type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver…

Comparison

Elevated Triglyceride-glucose (TyG) index vs Lower Triglyceride-glucose (TyG) index

Design

Cohort

Follow-up

median 53.4 months

Authors

JXJing XuWenzhou Medical University JZJianyong ZhaoAnhui Medical University ZDZhijuan DaiWenzhou Medical University

Discussion

Member takes

Implication

An elevated triglyceride-glucose index is a significant independent predictor of all-cause mortality and major adverse cardiovascular events in patients with co-existing T2DM and MASLD.

Key Points

This study aims to evaluate the prognostic significance of the triglyceride-glucose index in forecasting major cardiovascular events among patients with Type 2 diabetes mellitus and MASLD.
Retrospective cohort study involving 1021 patients diagnosed with T2DM and MASLD at Wenzhou Hospital from 2019 to 2022.
Cox proportional hazards model used to analyze the non-linear association between triglyceride-glucose index and outcomes like all-cause mortality and major adverse cardiovascular events.
Mediation analyses conducted to explore the mediating effects of estimated glomerular filtration rate and body roundness index.
62 all-cause mortality events and 101 major adverse cardiovascular events documented over a median follow-up of 53.4 months.
Increased triglyceride-glucose index linked to higher risk of mortality (HR = 1.85, 95% CI: 1.25, 2.73) and MACEs (HR = 1.71, 95% CI: 1.26, 2.33).
Mediation analysis indicated eGFR mediated 8.8% of the effect on all-cause mortality and 10.6% on major adverse cardiovascular events.

Study Design

Type

Cohort (n=2,364)

Multicenter

Yes

Structured PICO

Does an elevated triglyceride-glucose (TyG) index predict all-cause mortality and major adverse cardiovascular events in patients with concurrent T2DM and MASLD?

Population

2,364 patients with concurrent Type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease, followed for a median of 53.4 months.

Exposure

Elevated Triglyceride-glucose (TyG) index

Comparator

Lower Triglyceride-glucose (TyG) index

Outcome

All-cause mortality (ACM) and major adverse cardiovascular events (MACEs)composite

Main Result

Hazard Ratio: 1.71 (95% CI 1.26–2.33)

An elevated triglyceride-glucose index is a significant independent predictor of all-cause mortality and major adverse cardiovascular events in patients with co-existing T2DM and MASLD.

Cite This Study

Xu et al. (2026) conducted a cohort in Type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease (n=2,364). Elevated Triglyceride-glucose (TyG) index vs. Lower TyG index was evaluated on Major adverse cardiovascular events (MACEs) (HR 1.71, 95% CI 1.26-2.33). An elevated Triglyceride-glucose index was significantly associated with an increased risk of MACEs (HR 1.71; 95% CI 1.26-2.33) and mortality (HR 1.85; 95% CI 1.25-2.73) in patients with T2DM and MASLD.

synapsesocial.com/papers/6a377f3a24f042ddf4c59e39 https://doi.org/10.1186/s12933-026-03259-0

View Full Paper

Ask AI

Bookmark

Implication

An elevated triglyceride-glucose index is a significant independent predictor of all-cause mortality and major adverse cardiovascular events in patients with co-existing T2DM and MASLD.

Predictive significance of triglyceride-glucose index in forecasting adverse cardiovascular events among Type 2 diabetes mellitus patients with co-existing metabolic dysfunction-associated steatotic liver disease (MASLD): evidence from two cohort studies

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Main Result

Cite This Study

Predictive significance of triglyceride-glucose index in forecasting adverse cardiovascular events among Type 2 diabetes mellitus patients with co-existing metabolic dysfunction-associated steatotic liver disease (MASLD): evidence from two cohort studies

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Main Result

Cite This Study

Also Consider

Also Consider